The Pink Sheet -- Valeant Pharmaceuticals will have its work cut out for it when it attempts to convince a Food and Drug Administration advisory panel Aug. 11 that its antiepileptic drug ezogabine (Potiga) is worth the risks that forced almost one-third of patients who were taking it in clinical trials to stop.
